Abbott has announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System. Xience Xpedition 48, according to a company release is available in 48mm which is currently the longest stent.
Studies have indicated, according to the company press release, that physicians chose to use multiple shorter length stents to meet the challenges of treating long or lesions in up to 30% of interventional heart procedures, as conventional stent sizes may not always fully cover the lesion. It has been shown, however, that the use of a single stent instead of multiple stents may result in several procedural benefits, including the use of fewer devices, less exposure to X-ray during the procedure, and reduced procedure time—which could lead to economic benefits.
“With global economic pressures impacting hospitals and health care systems around the world, products like Xience Xpedition 48 may provide important cost savings to the system,” said Peter Smits, Maasstad Ziekenhuis, Rotterdam, The Netherlands. “I believe that this new treatment option, backed by the robust clinical outcomes of the Xience family of drug eluting stents, will help physicians in the treatment of long lesions.”
According to the company, the Xience Xpedition 48 is supported by strong clinical evidence from the Xience family of drug-eluting stents, including data from more than 53,000 patients across more than 100 studies with long-term outcomes up to five years. The safety of the Xience family of drug-eluting stents has been demonstrated in a number of clinical trials, according to Abbott, representative of routine clinical practice.
Xience Xpedition is available in diameters ranging from 2.25mm to 4mm, including a 3.25mm diameter, and lengths ranging from 8mm to 48mm.
